Giving the human papillomavirus vaccine to all U.S. women ages 12 to 45 could cut cervical cancer cases by 85% for 12-year-olds and by up to 55% for 45-year-old women, researchers found using a mathematical model.
Published in Brief:
Attest Health Care Advisors
|Biotechnology/Pharmaceutical Patent Attorney||
Coats and Bennett PLLC
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
Meridian Health Plan